Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-Positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor.
Phase of Trial: Phase II
Latest Information Update: 28 May 2016
At a glance
- Drugs Dasatinib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jul 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 31 Jul 2012 Planned End Date changed from 1 May 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History